We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

We give you many useful information about health

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Tampilkan postingan dengan label green. Tampilkan semua postingan
Tampilkan postingan dengan label green. Tampilkan semua postingan

Jumat, 30 September 2011

More deaths when green doctors place neck stents

AppId is over the quota
AppId is over the quota
By Frederik Joelving

NEW YORK | Wed Sep 28, 2011 6:21pm EDT

NEW YORK (Reuters Health) - People about to undergo a controversial stenting procedure in the neck might want to check their doctor's credentials first, researchers say.

According to a new study in the Journal of the American Medical Association, patients whose doctors do lots of the procedures are nearly half as likely to die over the next month as those in less-experienced hands.

During the treatment, called carotid stenting, doctors clean out cholesterol buildups in the carotid artery in the neck that sometimes cause strokes. Then they insert a small metal mesh tube, the stent, to prop the vessel open.

But if they're unfortunate, part of the cholesterol deposit might break off during the procedure and be released into the blood stream, producing the dreaded stroke the patient hoped to avoid.

"A little piece of it just flows upstream and can lodge in a smaller blood vessel in the brain," said Dr. Ethan A. Halm, who wrote an editorial about the new findings.

Based on Medicare records of nearly 25,000 procedures, the new study found a 30-day death rate of 1.4 percent in patients whose doctors placed at least 24 stents a year. By contrast, that death figure was as high as 2.5 percent when the doctors did six or fewer procedures annually.

The same pattern held true when comparing the initial and later procedures done by inexperienced doctors.

Dr. Brahmajee Nallamothu, a cardiologist at the University of Michigan in Ann Arbor who led the work, said the findings don't prove that lack of familiarity with the procedure explains the findings.

But he said that is likely to be the case, since there are no uniform standards for the training doctors need to undergo before they can perform carotid stenting.

"Patients shouldn't be shy about asking their physician who is going to be doing this procedure," Nallamothu told Reuters Health. "I think that it's a very fair question. If I were a patient, I would certainly want to know."

Halm added that carotid stenting is not the only alternative for patients with clogged arteries. The more common procedure is surgery, and some doctors recommend sticking just to medications. Especially when people have no symptoms, many believe doing surgery to clean them out is too hazardous.

With drugs alone, he told Reuters Health, the yearly stroke risk can be lowered to less than one percent, challenging the need for a procedure with significant risks.

And he added that the new study doesn't look at the total number of strokes caused by stenting, which tend to outnumber deaths by a factor of three.

"It's particularly important that people weigh the pros and cons of all therapies," said Halm.

In his view, the new results deal a blow to carotid stenting, which has become more and more common since it was approved in 2004. He estimated some 10,000 carotid stenting procedures were performed each year during the study, a number that has likely increased.

"There are a lot of tricky elements to the procedure," Halm said. "The article by Nallamothu shows that more people think they can do it well than actually can do it well."

If people decide that stenting is the right option for them, they might still have a hard time finding an experienced doctor to perform the procedure.

"The easiest piece of advice is to use an expert middle man," Halm said, adding that a neurologist can usually guide patients to an appropriate expert.

Nallamothu said he hoped the new study would spur the development of stricter training protocols and ensure that patients are followed more closely after stenting in the future.

SOURCE: bit.ly/n9JFW2 Journal of the American Medical Association, September 27, 2011.



View the original article here



Peliculas Online

Jumat, 23 September 2011

First European Embryonic Stem Cell Trial Gets Green Light

AppId is over the quota
AppId is over the quota

Health authorities in the U.K. approved on Thursday Europe's first clinical trial involving embryonic stem cells.

Surgeons at Moorfields Eye Hospital in London will treat 12 patients with Stargardt's macular dystrophy, a major cause of blindness in young people. Patients with Stargardt's gradually lose retinal pigment epithelial cells, or RPE cells, which are essential for maintaining the proper environment that encourages retinal cells to grow.

Patients in the U.K. trial will receive RPE cells grown from human embryonic stem cells. This is the second human trial to use such cells; the first was approved by the U.S. Food and Drug Administration (FDA) last November, which we described here. In both studies, the cells will be made by Massachusetts-based Advanced Cell Technology (ACT).

The purpose of the trial is to establish the safety of the treatment, so the dozen enrolled patients are at the most advanced stages of the incurable disease. They will receive anywhere from 50,000 to 200,000 cells, injected directly into the eye, behind the retina. Doctors expect that the transplanted cells will then start to grow in their new environment, replacing the diseased and dying ones that have robbed the patients of their vision.

The eye is a good site for testing such a treatment, since it is relatively protected from the immune system; the new cells may therefore be protected from destruction by overzealous defensive cells. The isolated nature of the eye's vitreous cavity, where the cells are injected, also makes it relatively easy for doctors to destroy the transplanted RPE cells should something go wrong, such as if the cells should start forming tumors or migrate to other areas.

The eye trials follow the first ever approved human trial of an embryonic stem cell based-therapy, approved in January 2009 in the U.S. to treat spinal cord injury. The FDA put that trial on hold after some animals receiving the stem cells developed cysts, but the company conducting the trial, Geron, provided additional safety data and new tests for detecting the unusual growths. Last summer the trial was once again allowed to move forward.

Embryonic stem cells could become an important source of replacement cells for a number of different diseases, including diabetes and Parkinson's. As Dr. James Barinbridge, a retinal surgeon at Moorfields and the UCL Institute of Ophthalmology, told the U.K.'s Guardian, "The ability to regenerate retinal cells from stem cells in the laboratory has been a significant advance and the opportunity to help translate such technology into new treatments for patients is hugely exciting. Testing the safety of retinal cell transplantation in this clinical trial will be an important step towards achieving this aim."

Alice Park is a writer at TIME. Find her on Twitter at @aliceparkny. You can also continue the discussion on TIME's Facebook page and on Twitter at @TIME.



View the original article here



Peliculas Online

Senin, 12 September 2011

HEALTH MANAGEMENT. Bright green cats are new tool in AIDS research

CHICAGO | Sun Sep 11, 2011 1: 24 pm EDT
Cats green radiant a strain of wheat with cells, infection by a virus have to CHICAGO (Reuters) - U.S. scientists, the cat AIDS, noting that can help resist caused to prevent that the disease in cats and AIDS research in people advance developed.
The study, published Sunday in the journal nature methods, involved inserting monkey genes, that the virus in feline eggs or ova, to block before they are fertilized.
The scientists also eingefügten jellyfish gene that the modified cells luminaires have a eerie green colour-make easy to see the modified genes.
Show they are resistant to feline immunodeficiency virus, or FIV, which causes AIDS in cats taken from the cats tests on cells.
"The offers the unprecedented ability, which impact the AIDS protection genes in AIDS threatened animals," said Dr. Eric Poeschla the Mayo Clinic in Rochester, Minnesota, who led the study, in a telephone interview.
Poeschla said, that in addition to humans, cats, and to a certain extent, chimpanzees, which causes only mammals that develop naturally occurring viruses, the AIDS.
"Cats of this all over the world suffer," he said.
Such as the human immunodeficiency virus or HIV in people, FIV will fight eradicate infection of T cells.
FIV infects primarily feral cats, of which there are billions in the world, half Poeschla said. It is of bite, mostly by men, transferred to the defense of their territory, but pet cats are also affected.
People and cats are proteins, as limiting factors, to combat the usually viral infection against HIV and FIV defenseless, because potent counter weapons developed the virus. But some monkey versions of this restriction can control of virus factors and one used the team gen from the rhesus monkey.
For the team, the staff in Japan, was the trick to the monkey-gen for the constraint factor-known as TRIMCyp - cats cells against infection by the virus to block.
GREEN FLUORESCENT PROTEIN GENE
To do that it uses a harmless virus to the genes in the eggs, a process to insert that monkeys, is already mice, pigs, sheep and marmoset in other mammals.
Easier to check, what cells had the monkey-gen, the team of a green fluorescent protein gene from the jellyfish Aequorea Victoria, which glow green makes them inserted.
"We have it easy just shining a light on the animal, or under the microscope for cells."
The method worked so well that almost all descendants from the modified eggs have the restriction factor genes. And, these defence proteins are body by the cat.
The team has put two of the three original luminous green cats, the litters, a total of eight kittens, the glowing cells, as well as have created to make.
But the point is not that the generations of disease-resistant, glowing to breed cats. Rather, the team plans to study these cats as a new way to the development of treatments for HIV and the cat version of the disease.
The work researchers said several uses.
"This technology can be applied to a variety of species, of which there is a clear many applications and potential benefits are," Dr. Laurence Tiley said of the University of Cambridge, in a statement.
"It will be interesting to see what enthusiasm in cats, they receive ability and offers of HIV and the neuro-biological research communities, and other research opportunities." "A representative non-Primate animal model would be to study a fantastic new tool for HIV Pathogenesis."
Poeschla team has taken so far only cells of animals and found resistant tested against FIV. But finally they plan, set the cats with the virus and see whether they are protected.
"If you could show that you protect, which transferred these animals, it will give us a lot of information on the protection of people would," said Poeschla.
For cats result can finally be new drugs for FIV, or gene therapy, he said.